📰 Objective Response Rate News
Page 10 - Objective Response Rate News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Objective Response Rate. Real-time updates on events, politics, business and more.
December 6, 2021
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
December 1, 2021
/PRNewswire/ -- Shenzhen Chipscreen Biosciences licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide...
December 1, 2021
/PRNewswire/ -- Shenzhen Chipscreen Biosciences licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide...
October 27, 2021
/PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd....
October 15, 2021
Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib
October 15, 2021
Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib in CLEAR/KEYNOTE-581 TrialPositive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS...
October 15, 2021
Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival Overall Survival and Objective Response Rate Benefit Compared to Sunitinib in CLEARKEYNOTE-581 Trial Positive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS Benefit Compared to Chemotherapy in KEYNOTE-775Study 309 Trial Merck known as MSD outside the United States and Canada, ...
August 11, 2021
/PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and...
April 10, 2021
(0) Ultimovacs ASA ("Ultimovacs", ticker ULTI), announced that it is presenting a poster today on the trial design of its ongoing Phase II INITIUM clinical study evaluating nivolumab and ipilimumab in combination with the Companys proprietary universal cancer vaccine, UV1, as first line treatment in patients with metastatic malignant melanoma, at the 2021 AACR Annual Meeting, held virtually from April 9 to April 14, 2021. The poster, titled, "Nivolumab and ipilimumab +/- UV1 vaccine as 1st line...
April 6, 2021
Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models - Results show seribantumab efficiently inhibited HER3 and the entire ERBB family signaling pathway and established a biologically effective dose range for tumors driven by an NRG1 fusion - - Seribantumab is currently being evaluated in the tumor-agnostic Phase 2 CRESTONE trial for patients with any solid tumor harboring an NRG1 fusion ...